Jeffrey Yordon Chairman, Founder, & CEO, Sagent Pharmaceuticals Jeffrey Yordon, founder of Sagent Pharmaceuticals, brings more than 40 years of injectables pharmaceutical experience to his company, gained by a career path that included senior level executive positions with a wide variety of pharmaceutical companies and culminated with his being an original founding member of Gensia Laboratories, LyphoMed, Faulding Pharmaceuticals and American Pharmaceutical Partners (APP), now called Fresenius. Most recently, while at APP, he held the positions of President, and Chief Operating Officer. All four of these companies had extraordinary growth during Mr. Yordon's tenure and each attained major milestones that are noteworthy: LyphoMed was sold to Fujisawa for $1 billion; Faulding was sold to Mayne and then subsequently sold to Hospira for $3.2 billion. Gensia Laboratories was sold to Teva Pharmaceuticals for $3.4 billion, and APP attained a market cap in excess of $6 billion and was sold to Fresenius for $5.5 billion. Mr. Yordon was a member of the Board of Directors of APP, Pharmaceutical Partners of Canada, Faulding Pharmaceuticals and Drug Source Company, as well as a board member of the Drug, Chemical & Associated Technologies Association (DCAT). His loyalty to his alma mater, Northern Illinois University, is evident by his membership on the university's Foundation Board, the Board of Directors of the Northern Illinois Executive Club, and his being an Alumni Advisor to NIU's Athletic Department as well as a regular visiting professor in the school of Business and Liberal Arts. Mr. Yordon received his BA degree from Northern Illinois University.